Pharmacologic treatment of binge eating disorder
Article first published online: 30 JUL 2003
Copyright © 2003 Wiley Periodicals, Inc.
International Journal of Eating Disorders
Special Issue: The Current Status of Binge Eating Disorder
Volume 34, Issue S1, pages S74–S88, 2003
How to Cite
Carter, W. P., Hudson, J. I., Lalonde, J. K., Pindyck, L., McElroy, S. L. and Pope Jr., H. G. (2003), Pharmacologic treatment of binge eating disorder. Int. J. Eat. Disord., 34: S74–S88. doi: 10.1002/eat.10207
- Issue published online: 30 JUL 2003
- Article first published online: 30 JUL 2003
- Manuscript Accepted: 28 MAR 2003
- binge eating disorder;
- appetite suppressants;
To review the findings from pharmacologic trials of binge eating disorder (BED) and to provide guidelines for pharmacologic treatment.
The literature was searched for studies of pharmacologic treatment of BED and related conditions, such as nonpurging bulimia nervosa.
Placebo-controlled studies of desipramine, fluvoxamine, fluoxetine, sertraline, citalopram, dexfenfluramine, sibutramine, and topiramate have demonstrated the efficacy of these agents in the treatment of BED. An open trial of venlafaxine has offered preliminary evidence for the efficacy of this medication. Guidelines for pharmacologic management of BED are provided.
The literature offers support for the use of agents from three categories of medication (antidepressants, appetite suppressants, and anticonvulsants) in the treatment of BED. © 2003 by Wiley Periodicals, Inc. Int J Eat Disord 34: S74–S88, 2003.